Related by context. All words. (Click for frequent words.) 76 DAS# [002] 75 Crohn Disease Activity 74 Score DAS 72 DAS# CRP 71 Health Assessment Questionnaire 70 SELENA SLEDAI 70 NIH CPSI 68 WOMAC 68 Index CDAI 68 Psoriasis Area 68 Visual Analog Scale 67 Score DAS# 67 Ocular Surface Disease 67 Expanded Disability Status 66 NIHSS 66 CDAI 66 International Prostate Symptom 66 BILAG 66 Visual Analog 65 Brief Psychiatric 65 Rating Scale UPDRS 65 Scale EDSS 65 PANSS 64 Severity Index PASI 64 Montgomery Åsberg Depression 64 Global Impression CGI 64 HAQ DI 64 IBDQ 64 UPDRS 64 YMRS 64 plus methotrexate 64 NIS LL 64 Montgomery Asberg Depression 64 Unified Parkinson Disease 64 Visual Analogue Scale VAS 64 mRS 63 pain subscale 63 Fibromyalgia Impact Questionnaire 63 WOMAC pain 63 subscale scores 62 HRQL 62 SGRQ 62 symptom severity 62 Ejection Fraction 62 Rating Scale MADRS 62 PANSS total 62 IPSS 62 erythrocyte sedimentation rate 62 Severity MSCS score 62 subscales 62 ADAS cog 62 Negative Syndrome 62 DAS# scores 62 Inventory BPI 62 enthesitis 62 estimated glomerular filtration 61 WOMAC TM 61 EDSS score 61 liver histology 61 PsA 61 preoperatively 61 Alzheimer Disease Assessment 61 HDRS 61 Pain Intensity 61 serologically active patients 61 Index CDAI score 61 pelvic lymphadenectomy 61 Score TOS 61 Solid Tumors criteria 61 PSQI 61 Negative Symptoms 61 subscore 61 QoL 60 FACIT Fatigue 60 BMI z 60 T2DM 60 Oswestry Disability Index 60 CDAI score 60 APACHE II 60 ACR# [002] 60 Abnormal Involuntary Movement 60 PCWP 60 Primary endpoints 60 Functional Assessment 60 IRLS score 60 Postoperatively 60 Brief Pain 60 Rating Scale BPRS 60 Score IPSS 60 Thrombolysis 60 UPDRS motor 60 Dyspnea 60 MADRS 60 pT3 60 HOMA IR 59 Scale PANSS 59 MADRS score 59 RECIST Response Evaluation Criteria 59 Physical Function 59 Severity Index 59 Status Scale EDSS 59 IRLS 59 SGOT 59 CNS LS 59 HRQoL 59 HAMD 59 OSDI 59 Scale EDSS score 59 aspartate aminotransferase 59 Response Evaluation Criteria 59 NYHA functional class 59 Skin sterol 59 pulmonary arterial 59 Secondary endpoints 59 nasal symptom 59 ADCS CGIC 59 methotrexate monotherapy 59 interrater reliability 59 alanine aminotransferase ALT 59 HADS 59 SF #v# 59 radiographic progression 59 Erectile Function IIEF 59 MetS 59 Ishak fibrosis score 59 EQ 5D 59 antibody titer 59 albumin excretion rate 59 tibiofemoral 59 Histologic 59 dyspnoea 59 endometrial thickness 59 Mean Symptom Complex 58 Symptom Severity 58 fasting insulin 58 left ventricular LV 58 serum PSA 58 polyarticular 58 Postoperative 58 PSADT 58 -#.# ± [002] 58 CCyR 58 alanine aminotransferase 58 radiographically 58 Index WOMAC 58 Physical Component 58 preoperative PSA 58 HAM D# 58 nonoperative treatment 58 DAS# remission 58 ADAS Cog 58 bronchial hyperresponsiveness 58 ACR# response 58 logistic regression analysis 58 histologic 58 Acute Physiology 58 visceral adiposity 58 baseline PASI 58 Beck Anxiety Inventory 58 KOOS 58 biopsy Gleason 58 EDSS 58 HRQOL 58 Erectile Function 58 Comorbidity 58 F FDG PET 58 Secondary endpoints included 58 seropositivity 58 subscores 58 Ankylosing Spondylitis 58 Geriatric Depression 58 femoral neck BMD 58 univariate analysis 57 IKDC 57 ALS Functional 57 Insulin sensitivity 57 Treatment Outcome 57 non menstrual pelvic 57 lumbar spine BMD 57 Y BOCS 57 Cystic Fibrosis Questionnaire Revised 57 infraspinatus 57 CFQ R 57 hip BMD 57 leukocyte counts 57 MMSE 57 mucosal healing 57 histologically proven 57 mTSS 57 AST ALT 57 rheumatoid factor 57 WOMAC scores 57 lymphocyte count 57 mineral density BMD 57 glycated hemoglobin levels 57 calculated creatinine clearance 57 Visual Analogue Scale 57 Seattle Angina Questionnaire 57 Scale cognitive subscale 57 QRS duration 57 glomerular filtration rate 57 aspartate aminotransferase AST 57 lactate dehydrogenase LDH 57 left ventricular diastolic 57 ASIA Impairment 57 Natalizumab 57 function subscale 57 DLQI 57 hematologic parameters 57 % CI #.#-#.# [007] 57 pT2 57 troponin T 57 postop 57 intraobserver 57 achieved ACR# 57 flow mediated dilation 57 quantitative computed tomography 57 Univariate 57 Scale Cognitive Subscale 57 synovitis 56 QIDS SR 56 intraabdominal 56 IIEF 56 serum triglycerides 56 elevated ALT 56 systolic function 56 posttreatment 56 mcg QD 56 NMIBC 56 Symptom severity 56 serum HBV DNA 56 lactate dehydrogenase 56 sulfasalazine 56 p = #.# [002] 56 apnea hypopnea index 56 CORE OM 56 semiquantitative 56 Fracture Risk 56 Total Nasal Symptom 56 Solid Tumors RECIST 56 Chronic Illness Therapy 56 glomerular filtration 56 confidence intervals CIs 56 P = .# 56 ACR Pedi 56 logistic regression analyzes 56 atrophic gastritis 56 point Likert scale 56 lopinavir r arm 56 abdominal pain abdominal discomfort 56 erection hardness 56 Epworth Sleepiness Scale 56 osteopenic 56 CIMZIA TM certolizumab pegol 56 postoperatively 56 Female Sexual Function 56 hematological parameters 56 hours postdose 56 Clinician Administered PTSD 56 Prognostic 56 HAM D 56 aminotransferases 56 demonstrated clinically meaningful 56 Pain Rating Scale 56 Rheumatoid 56 hemoglobin A1c levels 56 Histological 56 virological response 56 serum phosphate 56 State Examination MMSE 56 EORTC QLQ C# 56 alteplase 56 Secondary efficacy endpoints 56 HBeAg seroconversion 56 activated partial thromboplastin 56 â ‰ ¥ 56 serum aminotransferase levels 56 Wechsler Adult 56 clinically meaningful improvement 56 airway hyperresponsiveness 56 creatinine clearance 56 HER2 expression 56 univariate 56 Ankle Brachial Index 56 % CI #.#-#.# [005] 56 Patients Receiving 56 Symptom 56 UPDRS Part III 56 Main Outcome Measures 56 Mania Rating Scale 56 Depressive Symptoms 56 interobserver 56 multivariate analyzes 56 PASI scores 56 plus MTX 56 morphometric vertebral fractures 56 mineral density 56 platelet reactivity 55 perioperative complications 55 ropivacaine 55 CC genotype 55 hepatic enzymes 55 left ventricular systolic 55 SGPT 55 Endothelial function 55 FOLPI 55 mcg BID 55 MMSE scores 55 baseline HbA1c 55 gadolinium enhanced 55 biochemical relapse 55 periprocedural 55 atheroma volume 55 endoscopic remission 55 immunohistochemical analysis 55 Main Outcome Measure 55 gastroduodenal 55 somatostatin analog 55 GERD symptom 55 -#.# log# 55 lowest tertile 55 serum urate 55 nausea photophobia 55 secondary efficacy endpoint 55 Univariate analysis 55 nondiabetic patients 55 Lumbar spine 55 FDG-PET/CT 55 creatinine ratio 55 radical prostatectomy RP 55 patellofemoral 55 STN stimulation 55 pericardial effusion 55 Relapsing Remitting Multiple Sclerosis 55 neurocognitive function 55 MMSE score 55 serum ALT 55 Orthostatic Hypotension 55 diabetes mellitus DM 55 kg m² 55 receiving golimumab 55 colorectal adenoma 55 HbA 1c levels 55 intima media thickness 55 oxycodone CR 55 tissue oxygenation 55 LV ejection fraction 55 McMaster Universities Osteoarthritis 55 mL/min/#.# m 2 55 mg TID 55 BMI waist circumference 55 Preoperatively 55 CI -#.# 55 radiographic findings 55 Renal Function 55 International Prognostic Scoring 55 ANOVA 55 carotid intima media 55 metabolic parameters 55 fatty infiltration 55 Preoperative 55 CHADS2 55 Glasgow Coma Scale 55 postprocedure 55 multivariate Cox 55 C Reactive Protein 55 urothelial carcinoma 55 SLEDAI 55 Myocardial 55 Prostate Cancer Recurrence 55 dyspnea 55 CR nPR 55 Glomerular Filtration Rate 55 serum cortisol 55 Respiratory Symptoms 55 PANSS Positive 55 HbA 1c 55 highest tertile 55 Left Ventricular 55 clinico pathological 55 fasting plasma 55 arteriolar 55 Neuropsychiatric Inventory 55 ADCS ADL 55 urinary albumin 55 pCR 55 aminotransferase ALT 55 ≥ 55 bioavailable testosterone 55 symptomatic VTE 55 poststroke 55 BMI ≥ 55 Charlson comorbidity index 55 #q# deletion syndrome 55 serum testosterone 55 spirometric 55 carotid IMT 55 Index HAQ DI 55 subtrochanteric 55 #mg QD [002] 55 Ischemic Stroke 55 undetectable HBV DNA 55 % CI #.#-#.# [006] 54 lymphocytosis 54 CrCl 54 Hamilton Rating Scale 54 #.#mmHg 54 HBeAg negative patients 54 lateral radiographs 54 hsCRP levels 54 fasting plasma glucose 54 ejection fractions 54 autonomic dysfunction 54 acetabular dysplasia 54 histological subtype 54 SELENA SLEDAI score 54 TURBT 54 treated nonoperatively 54 ACR# ACR# 54 postoperative AF 54 Ashworth Scale 54 Secondary endpoints include 54 leukocyte count 54 Mortality Risk 54 mg QD 54 TNSS 54 adrenalectomy 54 HRCT 54 fasting glucose levels 54 ULORIC 54 8mg/kg 54 gadolinium enhancing 54 Patency 54 p = .# [002] 54 ipsilateral stroke 54 moderate renal impairment 54 RECIST criteria 54 FDG PET imaging 54 CI #.#-#.# [001] 54 macroalbuminuria 54 nonfatal MI 54 Hypertrophy 54 System IPSS 54 TNFalpha 54 Solid Tumors 54 methacholine challenge 54 tipranavir ritonavir 54 posttransplant 54 hallux valgus 54 leucopenia 54 urine albumin 54 Lower Limb 54 nonvertebral fractures 54 specific antigen PSA 54 Proteinuria 54 BPH symptom 54 aPTT 54 dactylitis 54 ALT AST 54 ACR# responses 54 arthralgias 54 SUVmax 54 HIV HCV coinfected 54 Mini Mental 54 baseline LDH 54 Apidra ® 54 CRp 54 recurrent VTE 54 Partial Response 54 depressive symptomatology 54 risk reducing salpingo 54 Ischemic 54 serum prostate 54 Meta Analysis 54 abdominal adiposity 54 inducible nitric oxide synthase 54 Glycemic Control 54 concomitant medications 54 CIMZIA TM 54 % CI #.#-#.# [008] 54 biochemical recurrence 54 denervation 54 virologic response 54 Stroke Scale 54 nerve conduction velocity 54 postoperative mortality 54 ACTEMRA TM 54 REYATAZ r arm 54 timepoints 54 annualized relapse 54 TEAEs 54 arterial oxygen saturation 54 Clinical Relevance 54 intra articular injection 54 progression TTP 54 renal allograft 54 Sentinel Lymph Node 54 multivariable analysis 54 Adalimumab 54 diastolic function 54 PCa 54 haematologic 54 PSA nadir 54 Autologous Stem Cell Transplantation 54 p = .# [001] 54 waist circumference WC 54 neutropaenia 54 serum IgG 54 GSTM1 54 adenotonsillectomy 54 -#.# mg dL [001] 54 placebo fluoxetine 54 ± SD 54 induration 54 nerve conduction velocity NCV 54 ritonavir boosted 54 Hb A1C 54 % CI #.#-#.# [003] 54 sensory neuropathy 54 HBeAg 54 total cholesterol triglycerides 54 corticosteroid injection 54 budesonide pMDI 54 glycated hemoglobin 54 pathologic fracture 54 elevated transaminases 54 serum phosphorous 54 XIENCE V PROMUS Stent 54 confirmed CCyR 54 TNF receptor 54 antithymocyte globulin 54 nodal metastasis 54 Tasigna prolongs 54 Follicular Lymphoma 54 ACE Inhibitors 54 medial compartment 54 Endothelial dysfunction 54 ABCB1 54 neutrophil counts 54 IL 1ß 54 Kellgren Lawrence 54 QTc interval 54 exploratory endpoints 54 logistic regression 54 Lesion 54 systolic dysfunction 54 refractory ischemia 54 umol L 54 Numeric Rating Scale 54 hypophosphatemia 54 ventricular repolarization 54 prespecified secondary 54 IQR 54 lumbar spine bone 54 mRNA expression 54 placebo p = 54 Non Alcoholic Steatohepatitis 54 neurologic impairment 54 CsA 54 serum HCV RNA 54 Distress Scale 54 corticosteroid dose 54 Functional Outcomes 54 Pioglitazone 54 Tumor Response 54 CR CRu 54 primary aldosteronism 54 postoperative complication 54 thyroglobulin 54 creatine kinase 54 irbesartan 54 bronchoalveolar lavage 54 inhibin 54 crossclamp 54 Interrater reliability 54 Baseline characteristics 53 extrapyramidal symptoms 53 -#.# log# copies mL 53 articular 53 microvessel density 53 galiximab 53 Stroke Scale NIHSS 53 binary restenosis 53 #.#/#.# mm Hg [003] 53 abdominal circumference 53 spontaneous bowel movements 53 Symptom Score 53 Alanine 53 Lymph node 53 Hemoglobin A1c 53 Oral Fingolimod 53 4mg/kg 53 dyssynchrony 53 Vasculitis 53 hepatic fibrosis 53 ug dose 53 cytogenetic response 53 serum thyroglobulin 53 Myocardial Ischemia 53 x ULN 53 logistic regression model 53 lymph node metastasis 53 LVEF 53 polymyalgia rheumatica 53 gadolinium enhancing lesions 53 adefovir treated 53 LV dysfunction 53 function subscales 53 CK MB 53 infliximab monotherapy 53 tipranavir r 53 Rating Scale 53 carotid artery intima media 53 prospectively stratified 53 bortezomib refractory 53 meniscectomy 53 parenchymal 53 reactive hyperemia 53 LDL HDL 53 plasma leptin 53 serum calcium levels 53 Soft Tissue Sarcoma 53 vasomotor 53 EDSS scores 53 immunostaining 53 esophageal carcinoma 53 perioperatively 53 pulmonary capillary wedge 53 HLA DR4 53 Myocardial Infarction TIMI 53 femoral neck 53 ecchymosis 53 partial remissions 53 rosuvastatin #mg 53 HBeAg negative 53 vitreous haze 53 NIHSS score 53 anterior uveitis 53 oral glucose tolerance 53 glycosylated hemoglobin HbA1c 53 p = #.# [004] 53 preoperative chemotherapy 53 salivary cortisol 53 tertile 53 ST Segment Elevation 53 calcaneal fractures 53 prostate cancer CaP 53 remission CR 53 HSCT 53 #.#ng/ml 53 POAG 53 ankle brachial index 53 NSTE ACS 53 aortic insufficiency 53 covariance 53 vitreous floaters 53 hepatic enzyme 53 Global Impression 53 coronary stenosis 53 lymphadenectomy 53 microalbumin 53 subscapularis 53 angiographically 53 hemorrhagic complications 53 comorbid anxiety 53 adjunctive placebo 53 plasma creatinine 53 depressive symptom 53 Knee Osteoarthritis 53 wedge resection 53 SSc 53 Vertebral 53 Ischaemic 53 Hamilton Anxiety Scale 53 juvenile idiopathic arthritis 53 hepatorenal syndrome 53 artery elasticity 53 mg BID dose 53 hemodynamic variables 53 infarct size 53 surgically resected 53 intima media thickness IMT 53 Kaplan Meier analysis 53 severe neutropenia 53 relapsed MM 53 #mg BID [003] 53 mg kg dose 53 preoperative intraoperative 53 Reperfusion 53 multiple logistic regression 53 nasal obstruction 53 serum IGF 53 Severe Asthma 53 TPV r 53 FOLFOX6 53 ankle dorsiflexion 53 carotid stenosis 53 morphologic characteristics 53 MACCE 53 Zometa hazard 53 Risk Stratification 53 intra articular 53 β blockers 53 Inflammatory Pain 53 -5 -6 53 interobserver reliability 53 abacavir lamivudine 53 serum leptin 53 sd = 53 QTcF 53 Stomatitis 53 Claudication 53 Cardiopulmonary bypass 53 distensibility 53 paresthesias 53 systolic hypertension 53 capillary density 53 anthropometric measures 53 extracapsular extension 53 tirofiban 53 Flu Cy 53 Bone Mineral Density 53 Ki# 53 Relapsing Multiple Sclerosis 53 RoACTEMRA 53 arthroplasties 53 nonmetastatic 53 FluCAM arm 53 HAQ 53 anemia hemoglobin 53 STRIDE PD 53 Timed Walk 53 intermittent claudication 53 MSLT 53 ADHD RS 53 thromboembolic events 53 Mental Component 53 myeloperoxidase 53 MDRD 53 p = #.# [003] 53 Platelet counts 53 airflow obstruction 53 synovial 53 CHADS 53 FDG uptake 53 transaminases 53 hyperreflexia 53 metastatic malignant 53 Rheumatoid Arthritis RA 53 #.#/#.# mmHg [001] 53 axillary lymph node 53 achieving PASI 53 placebo p 53 maximal treadmill 53 artery occlusion 53 nonfatal myocardial infarction 53 variance ANOVA 53 Hepatitis C Genotype 53 cortical atrophy 53 seropositive patients 53 renal artery stenosis 53 exhaled NO 53 achieved statistical significance 53 binary logistic regression 53 Tiotropium 53 lower extremity amputation 53 HBeAg positive patients 53 severe exacerbations 53 Endocrine Therapy 53 Subgroup analyzes 53 arthrodesis 53 doxorubicin cyclophosphamide 53 BARACLUDE ® 53 Bosentan 53 T2 lesions 53 Decitabine 53 Cardiac Resynchronization 53 retransplantation 53 EMBLEM TM 53 postoperative radiographs 53 nadolol 53 occlusive disease 53 peritumoral 53 fasting triglyceride levels 52 Free Survival PFS 52 mucosal inflammation 52 Thrombocytopenia 52 asymptomatic carotid stenosis 52 rhinoconjunctivitis 52 thromboembolic complications 52 NNT = 52 immunohistochemical 52 hypoglycemic events 52 ischemia driven 52 clodronate 52 unfractionated heparin UFH 52 elevated creatinine 52 DEXA scan 52 ‰ ¥ 52 ALT normalization 52 SSRI SNRI 52 dapagliflozin plus 52 ATACAND 52 clinically meaningful reductions 52 ankle brachial 52 chloride secretion 52 completely resected 52 Pearson correlation coefficients 52 perioperative mortality 52 detrusor 52 Pearson correlation coefficient 52 spontaneous bacterial peritonitis 52 Kaplan Meier method 52 mmHg diastolic 52 Neutrophil 52 SpO2 pulse rate 52 tapentadol ER 52 Coronary Artery Bypass Graft 52 Coronary Artery Calcium 52 claudication 52 Hemodynamic 52 Unfractionated Heparin 52 esomeprazole 52 HBV DNA 52 TKAs 52 confidence interval CI 52 hepatic lesions 52 latent celiac disease 52 varus 52 T1a 52 urinary N telopeptide 52 clinically meaningful improvements 52 Genant modified Sharp 52 Treatment Diabetic Retinopathy 52 convergent validity 52 Knodell necroinflammatory score 52 #mg BID [001] 52 etanercept 52 Cardiorespiratory fitness 52 oral antidiabetic medication 52 hindfoot 52 clinicopathologic 52 Global Impression Severity 52 varices 52 TLUS 52 mL/min/#.# m2 52 rs# [002] 52 serum potassium 52 Kinoid 52 univariate analyzes 52 thrombocytopenic 52 hyperalgesia 52 Neuropsychiatric Inventory NPI 52 fructosamine 52 Etanercept 52 resected 52 mycophenolate mofetil 52 URTI 52 serum bilirubin 52 tolvaptan 52 HER2 overexpression 52 nicardipine 52 node metastases 52 extra articular 52 hemodynamic measurements 52 ABC/3TC 52 dysuria 52 BPS IC 52 Renal dysfunction 52 LPS induced 52 adjunctive ABILIFY 52 genotypic resistance 52 platelet aggregation 52 p ≤ 52 Depression Inventory BDI 52 elevated serum creatinine 52 mg BID 52 postintervention 52 virologic responses 52 brachial artery flow 52 locomotor activity 52 log# copies mL 52 chemoradiation therapy 52 Key secondary endpoints 52 transcranial Doppler ultrasound 52 euthymic patients 52 intact parathyroid hormone 52 sUA 52 spine BMD 52 dermatologic toxicities 52 UPPP 52 hypertrichosis occurred 52 INVEGA ® 52 hemoglobin Hb 52 apolipoprotein B 52 plasma renin activity 52 T1 weighted images 52 ALND 52 Cardiotoxicity 52 inflammatory lesions 52 Symptom Checklist 52 adalimumab 52 % Confidence Interval 52 Visual acuity 52 BPRS PSS 52 arthropathy 52 nadroparin 52 mg/m2 dose 52 Statistically Significant 52 Logistic regression 52 unpaired t 52 prognostic variables 52 pentoxifylline 52 evaluable subjects 52 RAPAFLO R 52 Metastatic Renal Cell Carcinoma 52 nonvertebral fracture 52 invasive carcinomas 52 treat NNT 52 Outcomes Study 52 serum albumin 52 intraclass correlation coefficient 52 Erythema 52 Subgroup analysis 52 Depression Inventory 52 SBM frequency 52 tertiles 52 clinicopathological features 52 diastolic hypertension 52 Invasive Breast Cancer 52 certolizumab 52 VFQ 52 submaximal 52 hemoglobin A1c HbA1c 52 postinjury 52 hyperresponsiveness 52 posterolateral 52 ANCOVA 52 Immunohistochemical 52 Subgroup Analysis 52 akinesia 52 extracorporeal shock wave 52 Endarterectomy 52 serum creatinine 52 pharmacodynamic parameters 52 Pelvic Organ Prolapse 52 WAIS III 52 achieved CCyR 52 heterozygotes 52 CLINICAL PHARMACOLOGY 52 IFN alfa 52 IDDM 52 QD dosing 52 Coronary artery calcium 52 EBMT criteria 52 subclinical atherosclerosis 52 Hypotension 52 eNO 52 underwent resection 52 osteoarthritic 52 progesterone receptor PR 52 subthreshold depression 52 EF Domain 52 CIMZIA ™ 52 Primary Endpoint 52 cTnT levels 52 multivariate logistic regression 52 lymphovascular invasion 52 covariate 52 Raynaud phenomenon 52 atherosclerotic renal artery stenosis 52 Pathologic 52 clinicopathological 52 T1c 52 dose dependently 52 mean ± SEM 52 radical nephrectomy 52 CSBM 52 prednisone prednisolone plus 52 Mutational 52 D dimer 52 bothersome symptom 52 RECIST 52 stage IIIb IV 52 gemcitabine carboplatin 52 Papillary 52 Vertebral Fracture 52 experimentally induced 52 ETDRS 52 PaO 2 52 aortic regurgitation 52 Folfox 52 hemodynamically significant 52 response CCyR 52 thymoma 52 Peginterferon Alfa 2a 52 undergone radical prostatectomy 52 extraocular 52 recurrent glioblastoma multiforme